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Abstract
Formulated and sporulated cultures of Bacillus thuringiensis (Bt) have been widely used against insect pests, but 
after the advent of genetically modified plants expressing δ-endotoxins, the bioavailability of Cry proteins has been 
increased. For biosafety reasons their adverse effects should be studied, mainly for non-target organisms. Thus, we 
evaluated, in Swiss albino mice, the hematotoxicity and genotoxicity of four Bt spore-crystals genetically modified to 
express individually Cry1Aa, Cry1Ab, Cry1Ac or Cry2A, administered alone by gavage with a single dose of 27 mg/
Kg, 136 mg/Kg or 270 mg/Kg, 24 h, 72 h or 7 days before euthanasia. Binary combinations of these four spore-crystal 
proteins were also assayed at 270 mg/Kg with a single administration 24 h before euthanasia. Control mice received 
filtered water or cyclophosphamide at 27 mg/kg. For hematotoxicity evaluations, blood samples were drawn by cardiac 
puncture and processed in a multiple automated hematology analyzer; for genotoxicity analyses, micronucleus test 
was carried out in mice bone marrow cells. Spore-crystal administrations provoked selective hematotoxicity for the 3 
exposure times, particularly for erythroid lineage. A significant reduction in bone marrow cell proliferation demonstrated 
cytotoxic but not genotoxic effects. These effects persisted for all exposure times, becoming more evident at 7 days. 
Similar results were observed for binary combinations at 24 h, suggesting that further studies are required to clarify 
the mechanism involved in the hematotoxicity found in mice, and to establish the toxicological risks to non-target 
organisms, especially mammals, before concluding that these microbiological control agents are safe for mammals.
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Introduction
Agricultural production has been boosted by continued and 
indiscriminate applications of pesticides, mainly from the 1940s to 
the 1960s [1]. Unfortunately, this pest control management resulted in 
harmful outcomes such as the selection of resistant populations of insect 
pests, compromising the efficiency of control and forcing farmers to use 
increasingly high doses of pesticides [2-4]. Moreover, these chemical 
insecticides have harmful effects on human health and wildlife, leaving 
residues in food and the environment [2,3].
Among the viable alternatives for the replacement of these synthetic 
pesticides, entomopathogenic biological agents show potential for use 
in biological control programs and integrated production, because they 
leave few human side effects and have low impact on natural enemies 
and the environment [3,5,6]. In this context, Bacillus thuringiensis (Bt), 
a gram-positive, rod-shaped, spore-forming bacterium, is the most 
important biopesticide sold worldwide [7,8], having been used for over 
40 years by organic farmers who spray it as a foliar insecticide [7,9].
Bt is a microbial control agent (MCA) that produces a range of 
entomopathogenic toxins [10,11]. The most prominent feature of Bt is 
that during sporulation it synthesizes δ-endotoxins or insecticidal crystal 
proteins (ICPs), which are parasporal crystalline protein inclusions 
containing crystal proteins (Cry proteins or Cry toxins) as their major 
constituent [12–15]. These are toxic to larvae of susceptible insects and 
small invertebrates [1,16], and their use in combating predators from 
the Hymenoptera, Homoptera, Orthoptera, Coleoptera, Diptera and 
Lepdoptera Orders, the main cause of damage to agriculture, has been 
effective [7,17]. 
Apart from the wide use of formulated and sporulated cultures 
of Bt as foliar sprays, forming part of integrated pest management 
strategies against insect pests of agricultural crops [11,18], advances 
in biotechnology have allowed the development of many genetically 
modified plants expressing Bt δ-endotoxins [8,19,20]. Consequently, 
this gene has been widely cloned in different crops and then large 
amounts of such toxins are released into the environment. However, its 
adverse effects on non-target organisms are poorly understood [7,9,20]. 
The primary threat to the effectiveness of long-term use of Bt toxins 
is the evolution of resistance by pests [21], and one of the strategies 
to delay the emergence of resistant pests is the combined use of Cry 
toxins that are effective for the same target species. The simultaneous 
expression of binary combinations of Cry toxins minimizes the 
chance of insect resistance to Bt-plants [22]. In addition to the binary 
combinations, advances in genetic engineering promise the expression 
of multiple Cry toxins in Bt-plants, known as gene pyramiding 
[23]. Therefore, studies on non-target species are requirements of 
international protocols to verify the adverse effects of these toxins, 
ensuring human and environmental biosafety [8]. 
Due to its growing use in agricultural activities, Bt presence has 
already been detected in different environmental compartments such 
as soil and water [8]. Consequently, the bioavailability of Cry proteins 
has increased, and for biosafety reasons their adverse effects might 
be studied, mainly for non-target organisms. Studies are therefore 
needed to evaluate (i) Bt toxicity to non-target organisms [7,9]; (ii) the 
Mezzomo et al., J Hematol Thromb Dis 2013, 1:1
http://dx.doi.org/10.4172/2329-8790.1000104
Citation: Mezzomo BP, Miranda-Vilela AL, Freire IdS, Barbosa LCP, Portilho 
FA, et al. (2013) Hematotoxicity of Bacillus thuringiensis as Spore-crystal Strains 
Cry1Aa, Cry1Ab, Cry1Ac or Cry2Aa in Swiss Albino Mice. J Hematol Thromb Dis
1: 104. doi: 10.4172/2329-8790.1000104
J Hematol Thromb Dis
ISSN: 2329-8790 JHTD, an open access journal 
Page 2 of 9
Volume 1 • Issue 1 • 1000104
persistence of Bt toxin and its stability in aquatic environments [24]; 
and (iii) the risks to humans and animals exposed to potentially toxic 
levels of Bt through their diet [25]. 
Thus, we aimed to evaluate, in Swiss albino mice, the hematotoxicity 
and genotoxicity of four Bt spore-crystals genetically modified to 
express individually Cry1Aa, Cry1Ab, Cry1Ac or Cry2A, administered 
alone by gavage with a single dose of 27 mg/Kg, 136 mg/Kg or 270 mg/
Kg, 24 h, 72 h or 7 days before euthanasia, as well as their Cry binary 




The spore-crystals Cry1Aa, Cry1Ab, Cry1Ac and Cry2Aa from B. 
thuringiensis var. kurstaki were obtained in lyophilized form from the 
Germplasm Bank of the Brazilian Agricultural Research Corporation 
(Embrapa) through its National Genetic Resource and Biotechnology 
Research Center (Cenargen), Brasilia/DF, Brazil. These strains were 
genetically modified to express individually Cry1Aa, Cry1Ab, Cry1Ac 
or Cry2A, and bioassays using the purified proteins from these 
genetically modified (GM) Bt spore-crystals have been published [26].
Animals and experimental design
Swiss albino mice of both genders obtained from the animal 
facilities of the Faculty of the University of São Paulo (Ribeirão Preto/
SP, Brazil) were kept in the animal facility of the Laboratory of Genetics 
of the University of Brasilia (Brasília/Brazil), housed in plastic cages 
at room temperature (22°C ± 2°C) in a 12 h light/dark cycle with 
lights on at 6 a.m., and with free access to food and water. The period 
of acclimatization of the animals was at least seven days. Because 
quantitative differences in micronucleus induction have been identified 
between the sexes, but no qualitative differences have been described 
[27], and hematology reference values  for mice in the veterinary 
therapeutic guidelines do not differentiate sexes [28], a sample size (N) 
of 6 mice aged approximately three months, 50% male and 50% female, 
was used.
Four strains of lyophilized Bt spore-crystals, Cry1Aa, Cry1Ab, 
Cry1Ac and Cry2Aa, were resuspended in distilled water at 37°C, 
agitated for 10 minutes and administered orally by gavage, with a single 
dose of 27 mg/Kg, 136 mg/Kg or 270 mg/Kg, 24 h, 72 h or 7 days before 
euthanasia. Cry binary combinations (Cry1Aa+1Ab, Cry1Aa+1Ac, 
Cry1Aa+2Aa, Cry1Ab+1Ac, Cry1Ab+2Aa, Cry1Ac+2Aa) were 
also assayed at 270 mg/Kg with a single administration 24 h before 
euthanasia. Control mice received filtered water (negative control) or 
cyclophosphamide (CP, positive control) at 27 mg/kg. The minimum 
dose of Bt spore-crystal toxins was of 27 mg/Kg; the maximum dose 
(270 mg/Kg) was 10 times greater than the minimum dose, while 
the intermediate dose (136 mg/Kg) was equivalent to about half the 
maximum dose. In our previous experiments, exposures greater than 
270 mg/Kg had caused signs of toxicity and death, so this concentration 
was considered the maximum tolerated. 
The animals were anesthetized by an intraperitoneal administration 
of ketamine (80 mg/kg) plus xylazine (10 mg/kg). Blood samples 
collected by cardiac puncture (400 μL), using an insulin syringe 
containing EDTA as anticoagulant, were used to carry out hemogram in 
a multiple automated hematologic analyzer for veterinary use, Sysmex 
pocH-100iV Diff (Curitiba/Paraná, Brazil) calibrated for mice. Blood 
smear slides were also prepared and stained with Giemsa for visual 
assessments of anisocytosis (variation in size), poikilocytosis (change in 
shape of red blood cells - RBC), polychromasia (variation in erythrocyte 
coloration related to the maturation of RBC), hemagglutination 
and erythrocyte rouleaux. After euthanasia by cervical dislocation, 
bone marrow cells were surgically removed and the slides for the 
micronucleus (MN) test were prepared according to a standard method 
[29]. The genotoxic potential of spore-crystal toxins was assessed 
by quantification of MN in polychromatic erythrocytes (PCE) and 
normochromatic erythrocytes (NCE), and their possible cytotoxicity 
was evaluated by calculating the percentage of PCE. A total of 4000 cells 
was analyzed in light microscopy (1000X magnification), using a Zeiss 
Axioskop 2 microscope. For the 24-hour exposure, circulating blood 
and bone marrow of the mice were collected; for the 72-hour and 7-day 
exposure, only circulating blood was collected.
All procedures were reviewed and approved by the institutional 
Ethics Committee for Animal Research (Institute of Biological Science, 
University of Brasília), number 32942/2009.
Colony Forming Units (CFU)
In order to quantify the number of viable Bt spore-crystals, the 
colony forming units test (CFU) was performed according to Alves 
and Moraes (1998) [30]. For this, 0.1 g of each lyophilized spore-crystal 
was diluted and homogenized with a vortex in 10 mL of sterile distilled 
water. Thenceforward, five successive dilutions were made, using in 
each one 0.1 mL of previous dilution to 9.9 mL of sterile distilled water. 
Then, 0.1 mL of each one of the last three dilutions was plated in three 
replicates on a conventional culture medium (NYSM) and placed in 
an incubator at 30°C for 14 hours. The colonies of each replicate were 
counted and the average was calculated, with the result given in cells/
mL (Table 5).
Statistical analysis
Statistical analysis was carried out using SPSS (Statistical Package 
for the Social Sciences) version 15.0. Data were expressed as mean ± 
SEM (standard error of mean) and values of p<0.05 were considered 
statistically significant. The continuous variables were tested for normal 
distribution with Shapiro-Wilk. Possible differences among the groups 
analyzed were investigated through Kruskal-Wallis test, since the data 
were not normally distributed. For significant Kruskal-Wallis results, 
Mann-Whitney U test was performed to verify differences between the 
treatments (2-to-2 comparisons). P-values with statistical significance 
(p<0.05) were only considered when they also presented biological 
significance, according to the following criteria: (1) group C (negative 
control) compared to all groups; (2) group CP (positive control) 
compared to the treatments with the same exposure time or between 
CP of different exposure times; (3) the same toxins compared in the 
same exposure time but in different doses (dose-effect) or at 270 mg/
Kg in different exposure times (24 h, 72 h, 7 days); (4) different toxins 
compared to each other at 270 mg/Kg in the 24 h, 72 h and 7-day 
exposure; (5) binary combinations compared to single doses of those 
Cry present in the combinations at 270 mg/Kg, at 24 h of exposure; (6) 
binary combinations compared to each other.
Results
Erythrogram (Table 1)
24 hours of exposure: Oral administrations of single doses of 
Cry1Ab 136 mg/Kg (p=0.006), Cry1Ac 270 mg/Kg (p=0.011) and 
Cry2Aa 27 mg/Kg (p=0.006) significantly reduced MCH values, while 
Cry1Aa 27 mg/Kg (p=0.034) increased MCHC values. All Bt spore-
crystals promoted significant reductions in MCV values (p=0.004 for 
Cry1Aa 27 mg/Kg, p=0.003 for Cry1Ac 27 mg/Kg, and p=0.000 for the 
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others). For the visually assessed slides, microcytosis and hypochromia 
particularly increased for the treatments with Cry1Ab at 27 and 136 
mg/Kg, with hypochromia being more severe for the dose of 136 mg/
Kg; spherocytes were also very prevalent in these slides. Microcytosis 
with spherocyte presence was also observed in slides of Cry2Aa 270 
mg/Kg. Significantly decreased RDW were also observed for most 
Cry treatments, except for Cry1Ac at 27 and 270 mg/Kg (p=0.041 for 
Cry1Ab and Cry1Ac at 136 mg/Kg, p=0.002 for the other treatments). 
In the dose-effect evaluations, values  for RDW were significantly 
higher for Cry1Aa at 270 mg/Kg than at 136 mg/Kg (p=0.004). 
Binary combinations containing Cry1Ab+Cry2Aa (p=0.004) and 
Cry1Ac+Cry2Aa (p=0.000) caused significant reductions in MCH 
values, and all Cry combinations promoted significant reductions in 
VCM and RDW. For the visually assessed slides, a higher hypochromia 
to Cry1Ac+2Aa was observed. Among different binary combinations, 
Cry1Ac+Cry2Aa showed a higher RDW compared to Cry1Aa+Cry1Ab 
and Cry1Aa+Cry1Ac (p=0.041), which also occurred with Cry1Aa in 
respect to Cry1Aa+Cry1Ab (p=0.041).
72 hours of exposure: Compared to negative control, Cry1Ac 
270 mg/Kg continued to significantly reduce MHC values (p=0.040), 
while MCV and RDW were significantly reduced after treatment with 
CP, Cry1Ab, Cry1Ac and Cry2Aa. Among toxins, Cry1Aa showed a 
significant reduction in RBC (p=0.030), HGB (p=0.041) and HCT 
(p=0.015) values compared to Cry2Aa, and increased MCV compared 
to Cry2Aa (p=0.009) and Cry1Ac (p=0.026).
7 days of exposure: Cry1Ab 270 mg/Kg resulted in significantly 
reduced HGB (p=0.009) and HCT (p=0.002) values, while all Cry 
administrations significantly reduced MCH and MCV; the same 
occurred with MCV after CP treatment and with RDW after CP and all 
Cry administrations, except the Cry1Ab. For the visually assessed slides 













1 Filtered water, 7.53 ± 0.28 11.90 ± 0.44 30.38 ± 1.02 15.83 ± 0.09 39.12 ± 0.41 40.40 ± 0.40 17.83 ± 0.41
2 CP 27 mg/Kg, 24 h 7.60 ± 0.12 12.05 ± 0.26 30.57 ± 0.66 15.85 ± 0.16 39.45 ± 0.75 40.22 ± 0.46 16.80 ± 0.60
3 Cry1Aa 27 mg/Kg, 24 h 8.25 ± 0.13 12.78 ± 0.21 30.90 ± 0.36 15.50 ± 0.25 41.36 ± 0.38* 37.50 ± 0.43**.● 14.94 ± 0.54**.●
4 Cry1Aa 136 mg/Kg, 24 h 7.92 ± 0.14 12.19 ± 0.31 29.84 ± 0.68 15.37 ± 0.19 40.81 ± 0.32 37.64 ± 0.28**.● 14.16 ± 0.38**.●
5 Cry1Aa 270 mg/Kg, 24 h 8.35 ± 0.20 12.40 ± 0.29 31.08 ± 0.71 14.85 ± 0.16 39.88 ± 0.34 37.22 ± 0.12**.● 15.38 ± 0.21**.‡
6 Cry1Ab 27 mg/Kg, 24 h 8.17 ± 0.22 12.55 ± 0.42 31.13 ± 0.89 15.35 ± 0.22 40.30 ± 0.38 38.12 ± 0.21**.● 15.35 ± 0.31*
7 Cry1Ab 136 mg/Kg,  24 h 7.69 ± 0.09 11.23 ± 0.25 28.55 ± 0.62 14.62 ± 0.21**.● 39.35 ± 0.26 37.12 ± 0.42**.● 16.65 ± 0.56**
8 Cry1Ab 270 mg/Kg, 24 h 8.19 ± 0.16 12.63 ± 0.20 30.77 ± 0.53 15.45 ± 0.18 41.07 ± 0.33 37.60 ± 0.17**.● 15.70 ± 0.36**
9 Cry1Ac 27 mg/Kg, 24 h 7.98 ± 0.12 12.25 ± 0.24 30.42 ± 0.56 15.33 ± 0.20 40.28 ± 0.56 38.08 ± 0.22**.● 16.93 ± 0.36
10 Cry1Ac 136 mg/Kg, 24 h 8.11 ± 0.32 12.12 ± 0.40 29.92 ± 1.02 14.98 ± 0.22 40.53 ± 0.47 36.93 ± 0.23**.● 16.18 ± 0.67*
11 Cry1Ac 270 mg/Kg, 24 h 8.17 ± 0.35 11.98 ± 0.39 29.68 ± 1.07 14.67 ± 0.21* 40.42 ± 0.32 36.37 ± 0.35**.● 16.17 ± 0.67
12 Cry2Aa 27 mg/Kg, 24 h 8.24 ± 0.18 12.02 ± 0.15 29.95 ± 0.53 14.62 ± 0.22**.● 40.15 ± 0.35 36.40 ± 0.36**.● 15.02 ± 0.52**
13 Cry2Aa 136 mg/Kg, 24 h 7.86 ± 0.23 11.68 ± 0.33 29.05 ± 0.77 14.87 ± 0.10 40.22 ± 0.18 36.97 ± 0.31**.● 15.47 ± 0.30**
14 Cry2Aa 270 mg/Kg, 24 hk 7.75 ± 0.27 11.82 ± 0.37 28.97 ± 0.89 15.27 ± 0.17 40.82 ± 0.42 37.42 ± 0.29**.● 15.62 ± 0.34**
15 Cry1Aa+1Ab 270 mg/Kg, 24 h 8.30 ± 0.18 12.45 ± 0.30 31.15 ± 0.78 15.00 ± 0.10 ● 40.00 ± 0.23 37.53 ± 0.28**.● 14.87 ± 0.12**.●.a
16 Cry1Aa+1Ac 270 mg/Kg, 24 h 8.47 ± 0.42 12.93 ± 0.63 31.78 ± 1.25 15.30 ± 0.13 40.60 ± 0.48 37.63 ± 0.39**.● 14.85 ± 0.46**.●
17 Cry1Aa+2Aa 270 mg/Kg, 24 h 8.46 ± 0.14 12.70 ± 0.09 31.77 ± 0.24 15.03 ± 0.19 39.98 ± 0.27 37.57 ± 0.47**.● 14.95 ± 0.32**.●
18 Cry1Ab+1Ac 270 mg/Kg, 24 h 8.03 ± 0.15 12.17 ± 0.29 29.63 ± 0.78 15.15 ± 0.21 41.08 ± 0.28 36.88 ± 0.47**.● 15.48 ± 0.39**
19 Cry1Ab+2Aa 270 mg/Kg, 24 h 8.20 ± 0.16 11.95 ± 0.10 29.83 ± 0.35 14.58 ± 0.23** 40.07 ± 0.24 36.42 ± 0.48**.● 15.38 ± 0.43**
20 Cry1Ac+2Aa 270 mg/Kg, 24 h 8.33 ± 0.17 11.95 ± 0.21 30.50 ± 0.47 14.37 ± 0.33**.● 39.18 ± 0.48 36.70 ± 0.53**.● 15.82 ± 0.37**
P-values 24 h 0,075 0.072 0.179 0.000 0.002 0.000 0.000
21 CP 27 mg/Kg, 72 h 7.72 ± 0.28 11.65 ± 0.28 29.30 ± 0.76 15.13 ± 0.34 39.75 ± 0.27 38.03 ± 0.60*.● 15.02 ± 0.22**.●
22 Cry1Aa 270 mg/Kg, 72 h 6.86 ± 0.47a 10.77 ± 0.65a 26.73 ± 1.59a 15.77 ± 0.29 40.28 ± 0.45 39.15 ± 0.54 16.57 ± 0.67
23 Cry1Ab 270 mg/Kg, 72 h 7.92 ± 0.29 11.87 ± 0.26b 29.83 ± 0.81 15.02 ± 0.31 39.82 ± 0.44 37.75 ± 0.47** 15.40 ± 0.62**
24 Cry1Ac 270 mg/Kg, 72 h 8.17 ± 0.19 11.97 ± 0.44 30.28 ± 0.88 14.63 ± 0.27* 39.48 ± 0.46 37.07 ± 0.56** 16.40 ± 0.36*.○
25 Cry2Aa 270 mg/Kg, 72 h 8.30 ± 0.22 12.38 ± 0.31 30.67 ± 0.78 14.92 ± 0.16 40.38 ± 0.22 36.95 ± 0.52** 15.82 ± 0.10**.○
P-values 72 h 0,027 0.300 0.213 0.014 0.211 0.002 0.004
26 CP 27 mg/Kg, 7 days 8.10 ± 0.28 12.25 ± 0.34 30.82 ± 0.87 15.15 ± 0.13 39.75 ± 0.25 38.13 ± 0.41*.● 16.32 ± 0.59*
27 Cry1Aa 270 mg/Kg, 7 days 7.12 ± 0.30 10.77 ± 0.44a 26.88 ± 0.99a 15.13 ± 0.26 40.00 ± 0.25 37.80 ± 0.57** 16.38 ± 0.46*.a
28 Cry1Ab 270 mg/Kg, 7 days 6.53 ± 0.38b 9.68 ± 0.58**.b.b’ 24.55 ± 1.36**.b.b' 14.83 ± 0.15** 39.38 ± 0.40 37.63 ± 0.37** 17.02 ± 0.54
29 Cry1Ac 270 mg/Kg, 7 days 8.16 ± 0.10 12.17 ± 0.26 30.38 ± 0.48 14.92 ± 0.26* 40.03 ± 0.31 37.27 ± 0.47** 16.03 ± 0.33**
30 Cry2Aa 270 mg/Kg, 7 days 7.99 ± 0.20 11.90 ± 0.31 30.25 ± 0.77 14.88 ± 0.09* 39.33 ± 0.34 37.85 ± 0.28** 15.92 ± 0.41**
P-values 7 days 0.001 0.000 0.000 0.004 0.293 0.000 0.059
Total p-values 0.000 0.002 0.007 0.000 0.001 0.000 0.000
The data correspond to the means and to the standard error of mean (SEM).  RBC=Red Blood Cells; HGB=Hemoglobin; HCT=Hematocrit; MCV=Mean Corpuscular 
volume; MCH=Mean Corpuscular hemoglobin; MCHC=Mean corpuscular hemoglobin concentration; RDW=Red cell distribution width (represents an indication of the 
amount of variation − anisocytosis − in cell size); g/dL=grams per deciliter; fL=fentoliters; pg=picograms. P-values were generated by the Kruskall-Wallis test. Asterisks 
indicate significant (p<0.05) and highly significant (p<0.01) differences detected by the Mann Whitney U test in the comparisons with the negative control. The following 
symbols represent significant differences in respect to: ●=CP 24 h; ○=CP 72 h;  †= dose-effect for the dose of 27 mg/Kg; ‡=dose-effect for the dose of 136 mg/Kg; a= 
Cry1Aa 270 mg/Kg, 24 h; b=Cry1Ab 270 mg/Kg, 24 h; b’=Cry1Ab 270 mg/Kg, 72 h
Table 1: Results of erythrogram of Swiss albino mice treated with Bt spore-crystal Cry1Aa, Cry1Ab, Cry1Ac and Cry2Aa administered orally (per os, p.o.) 24 h, 72 h and 7 
days before euthanasia. Control mice received filtered water (negative control) or cyclophosphamide (CP – positive control) at 27 mg/Kg. 
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a higher hypochromia was observed for Cry1Aa, Cry1Ac, and Cry2Aa, 
more pronounced in the two first treatments. 
Comparing toxins, RBC, HGB and HCT were significantly lower 
for Cry1Ab than for Cry1Ac and Cry2Aa.
Leukogram (Table 2)
24 hours of exposure: In single doses only Cry1Ab 27 mg/Kg 
promoted a significant increase in lymphocyte frequency in comparison 
to the negative control (p=0.041). Cry1Ab significantly increased total 
leukocytes (white blood cells or WBC) and lymphocytes for the dose 
of 27 mg/Kg in respect to the doses of 136 mg/Kg (p=0.015 for WBC, 
p=0.002 for lymphocytes) and 270 mg/Kg (p=0.026 for total WBC, 
p=0.015 for lymphocytes), and increased neutrophils+monocytes for 
136 mg/Kg in respect to 270 mg/Kg (p=0.009). 
72 hours of exposure: Compared to negative control, only Cry1Aa 
caused significantly increased neutrophils+monocytes (p=0.003). 
Cry1Aa also showed increased WBC compared to Cry1Ab (p=0.015) 
and Cry1Ac (p=0.009), as well as neutrophils+monocytes in respect to 
Cry1Ab (p=0.016), Cry1Ac (p=0.004) and Cry2Aa (p=0.002).
7 days of exposure: Compared to the negative control, CP 
(p=0.026), Cry1Ac and Cry2Aa (p=0.041 for both) promoted a 
significant increase in WBC, and this result was related to increased 
neutrophils+monocytes (p=0.004 for CP; p=0.026 for Cry1Ac 
and Cry2Aa). Cry1Ab (p=0.002) caused a significant reduction in 
lymphocytes, while Cry2Aa (p=0.026) resulted in a significant increase 
in their number. Also, Cry1Aa (p=0.041) and Cry1Ab (p=0.026) caused 
a significant increase in eosinophils. Cry1A (p=0.009) and Cry1Ab 
(p=0.015) also showed significantly increased eosinophils compared 
to Cry2Aa. WBC and lymphocytes were also significantly reduced for 
Cry1Ab in respect to Cry1Ac and Cry2Aa.
G Treatment WBC(× 103/µL)
Lymphocytes
(× 103/µL)




1 Filtered water 4.63 ± 0.74 3.35 ± 0.55 1.22 ± 0.20 0.07 ± 0.05
2 CP 27 mg/Kg, 24 h 5.37 ± 0.77 3.73 ± 0.53 1.58 ± 0.34 0.05 ± 0.03
3 Cry1Aa 27 mg/Kg, 24 h 6.32 ± 0.85 4.94 ± 0.73 1.38 ± 0.14 0.00 ± 0.00
4 Cry1Aa 136 mg/Kg, 24 h 5.53 ± 0.52 4.20 ± 0.45 1.27 ± 0.11 0.06 ± 0.04
5 Cry1Aa 270 mg/Kg, 24 h 5.47 ± 0.77 3.93 ± 0.77 1.47 ± 0.31 0.07 ± 0.03
6 Cry1Ab 27 mg/Kg, 24 h 6.82 ± 0.62 5.13 ± 0.33* 1.68 ± 0.33 0.00 ± 0.00
7 Cry1Ab 136 mg/Kg, 24 h 4.60 ± 0.49† 2.60 ± 0.42† 1.92 ± 0.45 0.08 ± 0.03
8 Cry1Ab 270 mg/Kg, 24 h 4.60 ± 0.47† 3.53 ± 0.43† 0.98 ± 0.10‡ 0.08 ± 0.04
9 Cry1Ac 27 mg/Kg, 24 h 6.90 ± 0.89 4.25 ± 0.45 2.52 ± 0.66 0.13 ± 0.10
10 Cry1Ac 136 mg/Kg, 24 h 6.78 ± 1.66 4.00 ± 0.97 2.48 ± 0.56 0.30 ± 0.24
11 Cry1Ac 270 mg/Kg, 24 h 5.17 ± 0.66 3.55 ± 0.66 1.60 ± 0.37 0.02 ± 0.02
12 Cry2Aa 27 mg/Kg, 24 h 4.38 ± 0.63 2.43 ± 0.36 1.90 ± 0.53 0.05 ± 0.02
13 Cry2Aa 136 mg/Kg, 24 h 4.68 ± 1.06 3.05 ± 0.91 1.50 ± 0.32 0.13 ± 0.06
14 Cry2Aa 270 mg/Kg, 24 h 5.03 ± 0.78 2.98 ± 0.28 2.02 ± 0.73 0.03 ± 0.02
15 Cry1Aa+1Ab 270 mg/Kg, 24 h 5.97 ± 0.52 4.28 ± 0.54 1.67 ± 0.08b 0.02 ± 0.02
16 Cry1Aa+1Ac 270 mg/Kg, 24 h 4.10 ± 0.69 2.85 ± 0.58 1.20 ± 0.28 0.05 ± 0.02
17 Cry1Aa+2Aa 270 mg/Kg, 24 h 4.92 ± 0.84 3.38 ± 0.84 1.43 ± 0.52 0.10 ± 0.05
18 Cry1Ab+1Ac 270 mg/Kg, 24 h 4.72 ± 0.59 3.18 ± 0.51 1.42 ± 0.13b 0.12 ± 0.08
19 Cry1Ab+2Aa 270 mg/Kg, 24 h 4.78 ± 0.54 3.47 ± 0.48 1.28 ± 0.24 0.03 ± 0.02
20 Cry1Ac+2Aa 270 mg/Kg, 24 h 4.63 ± 0.70 3.13 ± 0.51 1.48 ± 0.40 0.02 ± 0.02
P-values 24 hours 0.454 0.095 0.758 0.486
21 CP 27 mg/Kg, 72 h 3.37 ± 0.78 2.40 ± 0.46 0.95 ± 0.41 0.02 ± 0.02
22 Cry1Aa 270 mg/Kg, 72 h 6.53 ± 0.82○ 3.42 ± 0.41 2.98 ± 0.43**.○.a 0.13 ± 0.08
23 Cry1Ab 270 mg/Kg, 72 h 4.27 ± 0.36 2.72 ± 0.16 1.48 ± 0.29 0.07 ± 0.03
24 Cry1Ac 270 mg/Kg, 72 h 3.72 ± 0.35 2.37 ± 0.35 1.25 ± 0.13 0.10 ± 0.06
25 Cry2Aa 270 mg/Kg, 72 h 4.80 ± 0.57 3.58 ± 0.46 1.18 ± 0.15 0.03 ± 0.02
P-values 72 hours 0.059 0.331 0.000 0.557
26 CP 27 mg/Kg, 7 days 7.22 ± 0.68*.○ 4.33 ± 0.40○ 2.82 ± 0.35**.●.○ 0.07 ± 0.03
27 Cry1Aa 270 mg/Kg, 7 days 6.70 ± 1.83 3.30 ± 0.77 3.15 ± 1.20 0.25 ± 0.08*.◊.a
28 Cry1Ab 270 mg/Kg, 7 days 3.90 ± 0.58◊ 1.85 ± 0.10**.◊.b.b’ 1.77 ± 0.42 0.28 ± 0.08*
29 Cry1Ac 270 mg/Kg, 7 days 6.58 ± 0.50*.c’ 3.85 ± 0.62 2.63 ± 0.60* 0.10 ± 0.04
30 Cry2Aa 270 mg/Kg, 7 days 7.85 ± 1.37* 5.33 ± 0.89*.d 2.48 ± 0.55*.d’ 0.03 ± 0.02
P-values 7 days 0.034 0.006 0.092 0.015
Total P-values 0.015 0.004 0.034 0.024
G= group. WBC= White Blood Cells. The data correspond to the means and to the standard error of mean (SEM).  P-values were generated by the Kruskall-Wallis test. 
Asterisks indicate significant (p<0.05) and highly significant (p<0.01) differences detected by the Mann Whitney U test in the comparisons with the negative control. The 
following symbols represent significant differences in respect to: ●=CP 24 h; ○=CP 72 h; ◊=CP 7 days; †=dose-effect for the dose of 27 mg/Kg; ‡=dose-effect for the dose 
of 136 mg/Kg; a=Cry1Aa 270 mg/Kg, 24 h; b=Cry1Ab 270 mg/Kg, 24 h; b’=Cry1Ab 270 mg/Kg, 72 h; c=Cry1Ac 270 mg/Kg, 24 h; c’=Cry1Ac 270 mg/Kg, 72h; d=Cry2Aa 
270 mg/Kg, 24 h; d’=Cry2Aa 270 mg/Kg, 72 h.
Table 2:  Results of leukogram of Swiss albino mice treated with Bt spore-crystal Cry1Aa, Cry1Ab, Cry1Ac and Cry2Aa administered orally (per os, p.o.) 24 h, 72 h, and 7 
days before euthanasia. Control mice received filtered water (negative control) or cyclophosphamide (CP – positive control) at 27 mg/Kg.
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Plateletgram (Table 3)
24 hours of exposure: In comparison with negative control, CP 
promoted a significant fall in platelet number (PLT, p=0.026), while a 
single dose of Cry1Aa 27 mg/Kg significantly increased PLT (p=0.009), 
decreased mean platelet volume (MPV, p=0.015) and platelet large 
cell ratio (P-LCR, p=0.026); the same decreased P-LCR occurring at 
136 mg/Kg (p=0.041). Cry1Ac 136 mg/Kg significantly increased 
MPV (p=0.019) and P-LCR (p=0.038), while Cry2Aa at 270 mg/Kg 
significantly decreased platelet distribution width (PDW, p=0.026). 
Regarding dose-effect, Cry1Aa at 136 mg/Kg showed reduced PLT 
(p=0.015) compared to 27 mg/Kg and reduced PDW (p=0.009) 
compared to 270 mg/Kg. Significantly increased values  of MPV, P-LCR 
and PDW were verified for Cry1Ac at 136 mg/Kg compared to 27 mg/
Kg and 270 mg/Kg (at 27 mg/Kg, p=0.010; at 270 mg/Kg, p=0.029). 
Cry1Ac at 136 mg/Kg also showed a significantly increased PDW in 
respect to the dose of 270 mg/Kg (p=0.038). Among toxins, at 270 mg/
Kg, PLT was significantly higher after treatment with Cry1Aa compared 
to Cry2Aa (p=0.041), while PDW was significantly higher for Cry1Ab 
than for Cry1A (p=0.041).
As regards the negative control, binary combinations significantly 
reduced levels as follows: Cry1Aa+Cry2Aa for PLT (p=0.002), 
Cry1Ab+Cry2Aa for MPV (p=0.024), and Cry1Ab+Cry1Ac for PDW 
(p= 0.030). Between combinations, Cry1Aa+Cry2Aa showed a lower 
PLT compared to Cry1Ab+Cry1Ac (p=0.015), and Cry1Aa+Cry2Aa 
presented higher MPV and RDW (p=0.036) in comparison with 
Cry1Ab+Cry2Aa.
Cry1Aa+Cry2Aa  showed significantly reduced PLT (p=0.009) and 
increased PDW (p=0.009) compared to Cry1Aa, which also presented 
lower PDW compared to Cry1Aa+Cry1Ab and Cry1Aa+Cry1Ac 
(p=0.015 for both), and Cry1Ab showed significantly higher PDW 







1 Filtered water 1219.00 ± 56.64 6.93 ± 0.10 10.88 ± 0.81 6.95 ± 0.11
2 CP 27 mg/Kg, 24 h 978.67 ± 93.57* 7.10 ± 0.30 11.23 ± 2.33 7.25 ± 0.24
3 Cry1Aa 27 mg/Kg, 24 h 1431.60 ± 27.40**.● 6.38 ± 0.15*.● 7.32 ± 1.15* 6.74 ± 0.05●
4 Cry1Aa 136 mg/Kg, 24 h 1243.57 ± 113.56† 6.56 ± 0.14 7.91 ± 1.14* 6.77 ± 0.07
5 Cry1Aa 270 mg/Kg, 24 h 1292.00 ± 74.24● 6.75 ± 0.15 11.15 ± 1.68 6.53 ± 0.07●.‡
6 Cry1Ab 27 mg/Kg, 24 h 1168.00 ± 73.22 6.62 ± 0.17 9.93 ± 1.10 6.63 ± 0.10●
7 Cry1Ab 136 mg/Kg, 24 h 1076.00 ± 148.54 6.85 ± 0.22 10.73 ± 1.74 6.75 ± 0.16
8 Cry1Ab 270 mg/Kg, 24 h 1020.50 ± 113.38 7.05 ± 0.16 12.33 ± 1.35 6.87 ± 0.11
9 Cry1Ac 27 mg/Kg, 24 h 1224.67 ± 58.93● 6.90 ± 0.09 9.63 ± 0.88 7.03 ± 0.10
10 Cry1Ac 136 mg/Kg, 24 h 955.83 ± 183.68 7.48 ± 0.10*.† 15.35 ± 0.80*.† 7.13 ± 0.09†
11 Cry1Ac 270 mg/Kg, 24 h 1213.50 ± 133.20 6.83 ± 0.16‡ 10.78 ± 0.78‡ 6.63 ± 0.08●.‡
12 Cry2Aa 27 mg/Kg, 24 h 1282.33 ± 110.10● 6.90 ± 0.16 10.24 ± 0.87 6.92 ± 0.14
13 Cry2Aa 136 mg/Kg, 24 h 1146.83 ± 62.99 6.97 ± 0.09 11.13 ± 0.94 6.9 ± 0.07
14 Cry2Aa 270 mg/Kg, 24 h 1057.50 ± 65.31 7.00 ± 0.10 11.78 ± 0.42 6.80 ± 0.13*
15 Cry1Aa+1Ab 270 mg/Kg, 24 h 1090.33 ± 69.82 6.80 ± 0.09 10.22 ± 0.61 6.83 ± 0.08a
16 Cry1Aa+1Ac 270 mg/Kg, 24 h 1187.33 ± 156.68 6.77 ± 0.13 9.78 ± 1.04 6.80 ± 0.06a
17 Cry1Aa+2Aa 270 mg/Kg, 24 h 942.67 ± 44.98**.a 7.00 ± 0.11 11.78 ± 1.17 6.88 ± 0.07a
18 Cry1Ab+1Ac 270 mg/Kg, 24 h 1171.67 ± 60.58 6.78 ± 0.16 11.16 ± 1.45 6.54 ± 0.10*
19 Cry1Ab+2Aa 270 mg/Kg, 24 h 1110.50 ± 69.8 6.57 ± 0.03*.b 9.23 ± 0.38b.d 6.57 ± 0.09
20 Cry1Ac+2Aa 270 mg/Kg, 24 h 1164.67 ± 105.33 7.00 ± 0.16 12.35 ± 1.34 6.75 ± 0.18
P-values 24 hours 0.048 0.015 0.044 0.005
21 CP 27 mg/Kg, 72 h 1112.17 ± 178.48 6.58 ± 0.15 8.14 ± 1.19 6.78 ± 0.12
22 Cry1Aa 270 mg/Kg, 72 h 1152.33 ± 96.43 6.65 ± 0.10* 7.67 ± 0.43** 6.78 ± 0.15
23 Cry1Ab 270 mg/Kg, 72 h 928.67 ± 92.55 6.93 ± 0.22 11.83 ± 1.55 6.58 ± 0.16
24 Cry1Ac 270 mg/Kg, 72 h 1095.50 ± 96.69 7.13 ± 0.23 12.80 ± 1.39 7.00 ± 0.16
25 Cry2Aa 270 mg/Kg, 72 h 1196.00 ± 67.53 7.16 ± 0.21 12.28 ± 2.12 7.04 ± 0.18
P-values 72 hours 0.454 0.077 0.010 0.316
26 CP 27 mg/Kg, 7 dias 1345.50 ± 158.38 6.67 ± 0.10 8.80 ± 0.81* 6.72 ± 0.09
27 Cry1Aa 270 mg/Kg, 7 dias 1002.50 ± 101.89a 7.23 ± 0.18a’ 12.07 ± 0.96a’ 7.05 ± 0.22
28 Cry1Ab 270 mg/Kg, 7 dias 589.50 ± 92.13b.b’ 7.47 ± 0.34 15.03 ± 2.23* 6.93 ± 0.29
29 Cry1Ac 270 mg/Kg, 7 dias 1289.00 ± 97.91 6.72 ± 0.10 9.85 ± 0.44 6.68 ± 0.09
30 Cry2Aa 270 mg/Kg, 7 dias 1205.33 ± 88.27 6.92 ± 0.09 9.98 ± 0.82 6.95 ± 0.10
P-values 7 days 0.000 0.006 0.034 0.388
Total P-values 0.005 0.002 0.002 0.020
The data correspond to the means and to the standard error of mean (SEM).  Platelet indices: platelet count (PLT), mean platelet volume (MPV), platelet large cell 
ratio (P-LCR) and platelet distribution width (PDW); fl=fentoliters. P-values were generated by the Kruskall-Wallis test. Asterisks indicate significant (p<0.05) and highly 
significant (p<0.01) differences detected by the Mann Whitney U test in the comparisons with the negative control. The following symbols represent significant differences 
in respect to: ●=CP 24 h; ○=CP 72 h; †=dose-effect for the dose of 27 mg/Kg; ‡=dose-effect for the dose of 136 mg/Kg; a=Cry1Aa 270 mg/Kg, 24 h; a’=Cry1Aa 270 mg/
Kg, 72 h;  b=Cry1Ab 270 mg/Kg, 24 h; b’=Cry1Ab 270 mg/Kg, 72 h; d=Cry2Aa 270 mg/Kg, 24 h
Table 3: Results of platelet gram of Swiss albino mice treated with Bt spore-crystal Cry1Aa, Cry1Ab, Cry1Ac and Cry2Aa administered orally (per os, p.o.) 24 h, 72 h and 
7 days before euthanasia. Control mice received filtered water (negative control) or cyclophosphamide (CP – positive control) at 27 mg/Kg. 
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compared to Cry1Ab+Cry2Aa (p=0.024). Similar results were observed 
for P-LCR, whose values  were significantly higher for Cry1Ab (p=0.048) 
and Cry2Aa (p=0.024) in comparison to the binary combination 
Cry1Ab+Cry2Aa.
72 hours of exposure: Cry1Aa promoted significantly decreased 
MPV (p=0.026) and P-LCR (p=0.002) compared to negative control; 
for the latter, values presented for Cry1Aa were also lower in respect 
to those presented for treatments with Cry1Ab, Cry1Ac (p=0.010) and 
Cry2Aa (p=0.017).
7 days of exposure: Compared to negative control, CP caused a 
significant reduction in P-LCR (p=0.041), while Cry1Ab promoted a 
significant increase in its values (p=0.048). Cry1Ab also presented 
a reduced PLT number compared to Cry1Ac (p=0.001) and Cry2Aa 
(p=0.003), and increased MVP compared to Cry1Ac (p=0.036). 
Micronucleus (MN) test (Table 4)
None of the tested Bt-toxins induced MN. Single doses of Cry1Aa 
136 mg/Kg (p=0.041), Cry1Ab at 27 (p=0.009) and 136 mg/Kg 
(p=0.026), Cry1Ac 136 mg/Kg and Cry2Aa 27 mg/Kg (p=0.009 for 
both) significantly decreased cell proliferation in mice bone marrow 
(%PCE) compared with negative control. Binary combinations of 
Cry1Aa+Cry2Aa, Cry1Ab+Cry2Aa and Cry1Ac+Cry2Aa (p=0.026 for 
all) also decreased the %PCE index.
Colony Forming Units (CFU) (Table 5)
CFU varied with Bt strain. Thus, although animals received 
Cry1Aa, Cry1Ab, Cry1Ac or Cry2Aa at 27 mg/Kg, 136 mg/Kg or 270 
mg/Kg, the number of viable Bt spore-crystals ingested by animals 
varied according to Bt strain.
Discussion
Since the late 1960’s, spore-crystals from B. thuringiensis have been 
an important ally in combating insect pests in agriculture, against 
insect vectors of human diseases and in biological pest control, through 
their use as a foliar insecticide [1,31] and, more recently, by inserting 
δ-endotoxin genes in transgenic Bt-plants [5]. A major environmental 
advantage of microbial Bt preparations and of genetically engineered 
insect-resistant plants expressing genes encoding δ-endotoxins is the 
greater specificity of δ-endotoxins to target species, compared with use 
of many synthetic chemical insecticides. However, despite their more 
targeted specificity, there may still be insects and other non-target 
organisms potentially affected by the δ-endotoxins, and extended 
exposure might affect their populations [8]. Thus, the Brazilian 
Collegiate Board of Directors of the National Sanitary Surveillance 
Agency (ANVISA) Nº 194/02 advocates evaluations of toxicity and 
pathogenicity of microbiological control agents (MCAs), given that 
little is known about their toxicological potential [32]. 
Group Treatment MN-NCE
Polychromatic erythrocytes (PCE)
MN-PCE Cellular proliferation index (%PCE)
1 Filtered water 2.00 ± 1.44 2.50 ± 1.43 52.61 ± 1.01
2 CP 27 mg/Kg 2.17 ± 0.48 3.50 ± 0.62 45.97 ± 1.21**
3 Cry1Aa 27 mg/Kg 0.40 ± 0.25● 3.00 ± 0.55 48.55 ± 1.54
4 Cry1Aa 136 mg/Kg 0.43 ± 0.20● 2.29 ± 0.36 49.28 ± 1.36*
5 Cry1Aa 270 mg/Kg 1.00 ± 0.37 3.67 ± 0.56 52.90 ± 1.57●
6 Cry1Ab 27 mg/Kg 1.67 ± 0.49 4.67 ± 0.88 45.92 ± 1.54**
7 Cry1Ab 136 mg/Kg 1.50 ± 0.43 3.33 ± 0.33 47.78 ± 1.28*
8 Cry1Ab 270 mg/Kg 1.00 ± 0.37 2.17 ± 0.95 52.91 ± 1.55●.†.‡
9 Cry1Ac 27 mg/Kg 1.33 ± 0.21 3.33 ± 0.76 49.49 ± 2.14
10 Cry1Ac 136 mg/Kg 2.50 ± 0.96 5.17 ± 0.98 44.92 ± 1.87**
11 Cry1Ac 270 mg/Kg 2.17 ± 0.40 4.00 ± 0.73 48.69 ± 1.73
12 Cry2Aa 27 mg/Kg 1.00 ± 0.52 0.83 ± 0.31● 47.06 ± 1.25**
13 Cry2Aa 136 mg/Kg 0.50 ± 0.22● 2.00 ± 0.45 47.93 ± 1.89
14 Cry2Aa 270 mg/Kg 0.17 ± 0.17● 0.50 ± 0.22●.‡ 48.63 ± 1.39
15 Cry1Aa+1Ab 270 mg/Kg 0.50 ± 0.22● 0.67 ± 0.33 45.02 ± 2.27a
16 Cry1Aa+1Ac 270 mg/Kg 0.33 ± 0.21●.c 0.83 ± 0.31●.a.c 46.72 ± 2.10
17 Cry1Aa+2Aa 270 mg/Kg 0.17 ± 0.17● 0.83 ± 0.31●.a 48.88 ± 0.56*
18 Cry1Ab+1Ac 270 mg/Kg 0.50 ± 0.22●.c 1.50 ± 0.43●.c 51.46 ± 1.43●
19 Cry1Ab+2Aa 270 mg/Kg 1.00 ± 0.45 2.83 ± 0.48d 46.50 ± 2.50*
20 Cry1Ac+2Aa 270 mg/Kg 0.50 ± 0.34●.c 1.83 ± 0.48c.d 46.51 ± 2.08*
P-values 0.001 0.000 0.026
The data correspond to the means and to the standard error of mean (SEM).  MN-NCE and MN-PCE = micronucleus test results for normochromatic erythrocytes (NCE) and 
polychromatic erythrocytes (PCE), respectively. P-values were generated by the Kruskall-Wallis test. Asterisks indicate significant (p<0.05) and highly significant (p<0.01) 
differences detected by the Mann Whitney U test in the comparisons with the negative control. The following symbols represent significant differences in respect to: ●=  CP; 
†=dose-effect for the dose of 27 mg/Kg; ‡=dose-effect for the dose of 136 mg/Kg; a=Cry1Aa 270 mg/Kg; c=Cry1Ac 27 mg/Kg; d=Cry2Aa 270 mg/Kg.
Table 4:  Micronucleus evaluation of bone marrow cells from Swiss white mice treated with Bt spore-crystal Cry1Aa, Cry1Ab, Cry1Ac and Cry2Aa administered orally (per 
os, p.o.) 24 h before euthanasia. Control mice received filtered water (negative control) or cyclophosphamide (CP – positive control) at 27 mg/Kg. 
Cry1Aa Cry1Ab Cry1Ac Cry2Aa
at 27 mg/Kg  (cells/mL) 2 × 107 3 × 107 4 ×107 2 × 107
at 136 mg/Kg  (cells/mL) 1 × 108 1 × 108 2 × 108 1 × 108
at 270 mg/Kg  (cells/mL) 2 × 108 3 × 108 4 × 108 2 × 108
Table 5: Results of Colony Forming Units (CFU) for Cry1Aa, Cry1Ab, Cr1Ac and Cry2Aa and quantification of the viable Bt spore-crystals ingested by the animals at the 
different concentrations used (27 mg/Kg, 136 mg/Kg and 270 mg/Kg). 
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It has been reported that Cry toxins exert their toxicity when 
activated at alkaline pH of the digestive tract of susceptible larvae, and, 
because the physiology of the mammalian digestive system does not 
allow their activation, and no known specific receptors in mammalian 
intestinal cells have been reported, the toxicity these MCAs to mammals 
would negligible [8,22,23]. However, our study demonstrated that Bt 
spore-crystals genetically modified to express individually Cry1Aa, 
Cry1Ab, Cry1Ac or Cry2A induced hematotoxicity, particularly to the 
erythroid lineage. This finding corroborates literature that demonstrated 
that alkali-solubilized Bt spore-crystals caused in vitro hemolysis in 
cell lines of rat, mouse, sheep, horse, and human erythrocytes and 
suggested that the plasma membrane of susceptible cells (erythrocytes, 
in this case) may be the primary target for these toxins [33].
It has been reported that strains of Cry toxins can be solubilized 
by alkaline buffer or a combination of alkaline buffer and reducing 
conditions, and that, although intravenous and subcutaneous 
administrations of 15-30 µg per gram body weight (0.4-0.9 mg per 
animal) of these alkali-soluble crystal proteins in Balb-C mice resulted 
in death, there were no toxic effects when orally administered [33]. In 
our study, lyophilized Bt spore-crystals resuspended in distilled water 
(and not in alkaline and/or reducing conditions) and orally administered 
at higher doses than the foregoing ones presented cytotoxic effects, 
particularly to the erythroid lineage of mice. Considering the increased 
risk of human and animal exposures to significant levels of these toxins, 
especially through diet, our results suggest that further evaluations are 
needed, with longer exposure of mammals to these diets, and involving 
clinical observations, before concluding that these microbiological 
control agents are safe to mammals. Cry1Ab induced microcytic 
hypochromic anemia in mice, even at the lowest tested dose of 27 mg/
Kg, and this toxin has been detected in blood of non-pregnant women, 
pregnant women and their fetuses in Canada, supposedly exposed 
through diet [34]. These data, as well as increased bioavailability of 
these MCA in the environment, reinforce the need for more research, 
especially given that little is known about spore crystals’ adverse effects 
on non-target species.
Because of its high mitotic index, hematopoietic tissue becomes the 
target of the adverse effects of many chemical substances entering the 
body. Some substances that act on bone marrow may have a selective 
effect, that is, they may be toxic to a given cell line [35]. Our study found 
selective cytotoxicity for the erythroid lineage and showed differences 
in the dose response curves of Bt spore-crystals genetically modified 
to express individually Cry1Aa, Cry1Ab, Cry1Ac or Cry2A. After 24 
hours of exposure, Cry1Ac and Cry2Aa showed a non-monotonic dose 
response curve, where Cry2Aa presented a U-shaped dose response 
curve, with high responses at both low and high levels of contamination, 
while the Cry1Ac response curve was shaped like an inverted U with 
the greatest response in intermediate ranges. On the other hand, 
Cry1Ab seemed to have an effect similar to hormesis, where lower toxin 
doses (such as 27 and 136 mg/Kg) increased the body’s tolerance for 
greater toxicity (such as 270 mg/Kg), while Cry1Aa seemed to maintain 
almost the same behavior, regardless of the dose. These differences 
among Cry toxins were already somewhat expected, since they have a 
defined spectrum of insecticidal activity, each of which is specific for 
some species belonging to a particular order of insects, according to 
their affinities for specific receptors on their target organisms [10,36]. 
Additionally, although results of CFU showed fewer viable spores/mL 
for Cry2Aa and Cry1Aa than for Cry1Ab and Cry1Ac, at 270 mg/mL 
the cytotoxic effects of Cry2Aa and Cry1Aa seemed higher compared 
to Cry1Ab and Cry1Ac. 
Knowledge of the genotoxic potential of chemical industrial agents 
or those naturally present in the environment is essential information 
for regulatory agencies, regarding the establishment of risk for humans 
[37]. Since micronuclei in interphase cells result from chromosomal 
breaks or chromosomal lagging, the MN test is most widely used for 
the detection of clastogenic and aneugenic agents [29,38,39]. For the 
fish species Danio rerio, it has been reported that Cry1Aa significantly 
increased the frequency of micronuclei in peripheral blood of 
erythrocytes, while Cry1Ab, Cry1Ac, and Cry2A did not present 
genotoxicity [40]. In our study, all evaluated spore-crystals in single or 
binary combinations were hematotoxic and cytotoxic to the mice bone 
marrow, but not genotoxic, and this could indicate differences among 
vertebrates. 
In the biological control of pests, a combination of different mixtures 
of Bt spore-crystal strains is also used. Also, a second generation of 
Bt-plants expressing two different Cry toxins has been developed 
to avoid insect resistance. There are several examples of transgenic 
plants with dual Bt gene insertion, such as Bollgard® II RR Flex cotton 
(Cry1Ac+Cry2Ab) and maize (Cry1Ac+Cry2Ab) [41]. Consequently, 
various interactive processes may occur, such as additivity, synergism, 
potentiation or antagonism [41,42]. However, to date, there are 
few studies on the cytotoxicity of conjugated Bt toxins for different 
organisms, and no studies were found in the literature evaluating the 
potential toxic and genotoxic effects of binary combinations of Cry 
toxins for non-target organisms. Our results demonstrated that the 
binary combinations of Cry1Ac+Cry2Aa and Cry1Ab+Cry2Aa were 
also hematotoxic to the erythroid lineage in particular. Furthermore, 
these binary combinations and also Cry1Aa+Cry2Aa were cytotoxic to 
the bone marrow cells in that they reduced the %PCE.
Literature has shown that Bt toxins are generally nontoxic and do 
not bioaccumulate in fatty tissue or persist in the environment [23], 
but our study demonstrated that all Cry at 270 mg/Kg showed a more 
pronounced cytotoxic effect on the erythroid lineage from 72 hours 
of exposure onwards, and that these effects were more pronounced 
after 7 days of exposure. After 7 days of exposure, Cry1Ab was toxic 
showing alterations in the hematological parameters of the exposed 
mice. It is well known that processes or substances that cause damage 
in the hematopoietic stem cell or bone marrow stroma of mice can 
also cause a decrease in WBC count [43]. Indeed, Cry1Ab significantly 
decreased MCH, MCV, and RDW and also decreased the number of 
PLT, which was non-significant in relation to the negative control but 
was substantially lower than the reference values for mice (900-1600 
× 103/μL) [43], as well as significantly increased P-LCR and decreased 
lymphocyte number. The profile of observed cytotoxic effects of these 
Cry toxins can be related to their high concentrations and the exposure 
time. Such exposures at these high concentrations are not commonly 
found in the environment. 
In mice, the inflammatory response is often associated with both 
increased lymphocytes and neutrophils, and small changes in the 
number of neutrophils may be biologically significant and reflected 
in the total leukocyte count [43]. In this context, our study showed a 
higher inflammatory response for Cry1Aa 270 mg/Kg after 72 hours 
of exposure and for Cry1Ac and Cry2Aa at 270 mg/Kg after 7 days of 
exposure. Immunophenotypic changes have been demonstrated in the 
intestine and peripheral sites of young and old mice after ingestion 
of Bt corn MON810 encoding the active form of Cry1Ab [44], and 
intragastric administration of Cry1Ac prototoxin has induced secretion 
of mucosal antibodies in mice [45]. Our results corroborate these 
findings for Cry1Ac and also demonstrate leukogenic activity for other 
spore-crystals not yet reported in the literature. 
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In conclusion, results showed that the Bt spore-crystals genetically 
modified to express individually Cry1Aa, Cry1Ab, Cry1Ac or Cry2A 
can cause some hematological risks to vertebrates, increasing their toxic 
effects with long-term exposure. Taking into account the increased risk 
of human and animal exposures to significant levels of these toxins, 
especially through diet, our results suggest that further studies are 
required to clarify the mechanism involved in the hematotoxicity found 
in mice, and to establish the toxicological risks to non-target organisms, 
especially mammals, before concluding that these microbiological 
control agents are safe for mammals.
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